GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
GlaxoSmithKline plc (GSKN) - Net Assets
Latest net assets as of September 2025: MX$15.75 Billion MXN
Based on the latest financial reports, GlaxoSmithKline plc (GSKN) has net assets worth MX$15.75 Billion MXN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (MX$61.34 Billion) and total liabilities (MX$45.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | MX$15.75 Billion |
| % of Total Assets | 25.68% |
| Annual Growth Rate | 4.8% |
| 5-Year Change | -37.11% |
| 10-Year Change | 47.4% |
| Growth Volatility | 121.35 |
GlaxoSmithKline plc - Net Assets Trend (2013–2024)
This chart illustrates how GlaxoSmithKline plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GlaxoSmithKline plc (2013–2024)
The table below shows the annual net assets of GlaxoSmithKline plc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | MX$13.09 Billion | +2.27% |
| 2023-12-31 | MX$12.79 Billion | +26.73% |
| 2022-12-31 | MX$10.10 Billion | -52.69% |
| 2021-12-31 | MX$21.34 Billion | +2.57% |
| 2020-12-31 | MX$20.81 Billion | +13.35% |
| 2019-12-31 | MX$18.36 Billion | +399.92% |
| 2018-12-31 | MX$3.67 Billion | +5.25% |
| 2017-12-31 | MX$3.49 Billion | -29.70% |
| 2016-12-31 | MX$4.96 Billion | -44.10% |
| 2015-12-31 | MX$8.88 Billion | +79.86% |
| 2014-12-31 | MX$4.94 Billion | -36.82% |
| 2013-12-31 | MX$7.81 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GlaxoSmithKline plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2284.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | MX$7.80 Billion | 57.03% |
| Other Components | MX$5.88 Billion | 42.97% |
| Total Equity | MX$13.67 Billion | 100.00% |
GlaxoSmithKline plc Competitors by Market Cap
The table below lists competitors of GlaxoSmithKline plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Semiconductor Manufacturing Intl Co
SHG:688981
|
$99.08 Billion |
|
Zijin Mining Group Co Ltd Class A
SHG:601899
|
$99.09 Billion |
|
Air Liquide SA
PA:AI
|
$99.38 Billion |
|
UniCredit S.p.A.
WAR:UCG
|
$99.58 Billion |
|
Southern Company
NYSE:SO
|
$97.89 Billion |
|
CNOOC Limited
SHG:600938
|
$97.85 Billion |
|
China Merchants Bank Co Ltd Class H
PINK:CIHHF
|
$97.81 Billion |
|
China Shenhua Energy Co Ltd
PINK:CSUAY
|
$97.80 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GlaxoSmithKline plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,347,000,000 to 13,671,000,000, a change of 324,000,000 (2.4%).
- Net income of 2,575,000,000 contributed positively to equity growth.
- Dividend payments of 2,444,000,000 reduced retained earnings.
- New share issuances of 20,000,000 increased equity.
- Other factors increased equity by 173,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | MX$2.58 Billion | +18.84% |
| Dividends Paid | MX$2.44 Billion | -17.88% |
| Share Issuances | MX$20.00 Million | +0.15% |
| Other Changes | MX$173.00 Million | +1.27% |
| Total Change | MX$- | 2.43% |
Book Value vs Market Value Analysis
This analysis compares GlaxoSmithKline plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 310.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | MX$-0.01 | MX$1040.00 | x |
| 2018-12-31 | MX$0.88 | MX$1040.00 | x |
| 2019-12-31 | MX$2.29 | MX$1040.00 | x |
| 2020-12-31 | MX$2.90 | MX$1040.00 | x |
| 2021-12-31 | MX$3.01 | MX$1040.00 | x |
| 2022-12-31 | MX$2.59 | MX$1040.00 | x |
| 2023-12-31 | MX$3.29 | MX$1040.00 | x |
| 2024-12-31 | MX$3.35 | MX$1040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GlaxoSmithKline plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.84%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.21%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 4.35x
- Recent ROE (18.84%) is below the historical average (64.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 77.69% | 20.51% | 0.63x | 6.01x | MX$4.74 Billion |
| 2014 | 64.65% | 11.98% | 0.57x | 9.54x | MX$2.33 Billion |
| 2015 | 164.69% | 35.20% | 0.45x | 10.45x | MX$7.91 Billion |
| 2016 | 81.14% | 3.27% | 0.47x | 52.56x | MX$799.60 Million |
| 2017 | 0.00% | 5.08% | 0.54x | 0.00x | MX$1.54 Billion |
| 2018 | 83.10% | 11.75% | 0.53x | 13.32x | MX$3.19 Billion |
| 2019 | 40.73% | 13.76% | 0.42x | 6.99x | MX$3.50 Billion |
| 2020 | 39.41% | 16.86% | 0.42x | 5.51x | MX$4.29 Billion |
| 2021 | 29.13% | 12.85% | 0.43x | 5.25x | MX$2.88 Billion |
| 2022 | 141.12% | 51.00% | 0.49x | 5.68x | MX$13.90 Billion |
| 2023 | 36.92% | 16.25% | 0.51x | 4.42x | MX$3.59 Billion |
| 2024 | 18.84% | 8.21% | 0.53x | 4.35x | MX$1.21 Billion |
Industry Comparison
This section compares GlaxoSmithKline plc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.